BDX (BD) Company Assets

Official company branding of BD (BDX)

This daily price chart for Becton Dickinson & Co (BDX), currently valued at 38565.57, reflects the impact of implementing smart pumps and molecular diagnostics. High-yield M&A deals and equipment for chronic pathology therapy are driving the growth in market capitalization. Basic consumables with steady demand provide a consistent cash flow. Such a model transforms the production of simple instruments into a reliable cash cow with immense momentum.

BDX - Becton Dickinson Company Total Assets over the range 07/04/2022 - 10/30/2026

Financial and market metric breakdowns for Becton, Dickinson and Company (BDX)

- price and consensus price forecast:
Stock Quotes bd.com|BDX - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Becton Dickinson & Company|BDX - Enterprise Value
- balance sheet equity data:
Equity per Share Becton Dickinson|BDX - Book Capitalization|Market Capitalization to Book Value bd.com|BDX - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Becton Dickinson & Co|BDX - Long-Term Debt to Capital|Short-Term Debt to Capital Becton Dickinson & Company|BDX - Company Debts|Debt to Book Capitalization Ratio Becton Dickinson & Company|BDX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Becton Dickinson|Interim Coverage Ratio bd.com
- earnings and market ratios statistics:
BDX - Company Net Income
Basic company analysis:bd.com, BDX
Core merchandise of Becton, Dickinson and Company

The efficiency of Becton Dickinson & Co (BDX) depends directly on clinic equipment levels and the stability of medical technology supplies. Total assets, calculated inversely via ROA, measure the aggregate volume of resources deployed to generate profit. Growth in this metric signals an expansion of production capacity; however, excessive debt leverage increases financial risks. By analyzing total asset trends (via ROA) on GURU.Markets, an investor assesses the stability of the company's asset base.

Key competitors

Cumulative Company Assets intuitive.com|DHR (Danaher) - Company Total Assets|Company Assets STERIS PLC STE|Company Total Assets WST|Baxter Healthcare - Total Business Assets|Company Total Assets MASI (Masimo Corporation)|Company Total Asset Base stevanatogroup.com (STVN)|Teleflex - Company Total Assets|Merit Medical Systems, Inc. (MMSI) - Cumulative Company Assets|NVST: Company Total Assets|ICU Medical Inc. (ICUI) - Company Total Assets|Aggregate Company Assets DENTSPLY SIRONA Inc.|Aggregate Company Assets LMAT|Cumulative Company Assets ATRC (AtriCure)|STAA (STAAR Surgical Co.) - Aggregate Asset Value|Company Total Assets NAGE (niagenbioscience.com)|Company Total Asset Base ZimVie Corp (ZIMV)|ANGO - Aggregate Company Assets|CERS (cerus.com) - Total Business Assets|Teknova (TKNO) - Aggregate Company Assets|MGRM - Company Total Asset Base|Cumulative Company Assets STSS|INFU (InfuSystem Inc) - Aggregate Business Assets|Aggregate Company Assets Utah Medical Products (UTMD)|KRMD (korumedical.com) - Aggregate Asset Value|Nyxoah - Cumulative Company Assets|Company Total Assets Microbot Medical, Inc. MBOT|PDEX - Aggregate Company Assets|Zentek Corp (ZTEK) - Cumulative Company Assets|ELUT: Company Total Assets|Company Assets milestonescientific.com (MLSS)|Aggregate Company Assets NEXGEL|Total Business Assets RVP (Retractable Tech)|Cumulative Company Assets HBIO (Harvard Bioscience)|Aggregate Business Assets FEMY|Aggregate Company Assets Meihua Medical Technologies Co., Ltd. MHUA|Company Total Asset Base Predictive Oncology Inc (POAI)|Callan JMB Corp - Company Total Assets|ATRI: Aggregate Company Assets|NURO: Company Total Assets